A comparison of entecavir and lamivudine for HBeAg-positive chronic hepatitis B.

By Ting Chang, R. Gish, R. D. de Man, A. Gadano, J. Sollano, Y. Chao, A. Lok, K. Han, Z. Goodman, Jin-shui Zhu and 5 more. New England Journal of Medicine, 2006

1,409 citations recorded by the source corpus.

Subfields: Epidemiology, Hepatology

View Paper: https://www.semanticscholar.org/paper/5a734c0b8238a83ae17a1bb2915fe0a031d1a6b6

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

In Epidemiology

1. G. Dusheiko
2. X. Forns
3. J. Pawlotsky

In Hepatology

1. D. Moradpour
2. G. Dusheiko
3. X. Forns
4. J. Pawlotsky

Citations in the corpus

• Tenofovir disoproxil fumarate versus adefovir dipivoxil for chronic hepatitis B. (2008, neutral): “ 14 ) 14 )”
• Asian-Pacific consensus statement on the management of chronic hepatitis B: a 2008 update (2008, background): “Pivotal phase III randomized lamivudine controlled trials showed that 1-year entecavir (0.5 mg/day) is superior to lamivudine in reducing HBV-DNA in both HBeAg-positive (-6.9 log vs. -5.4 log; P \ 0.0001; HBV-DNA \ 300 copies/ml in 67% vs. 36%) [ 86 ] and HBeAg-negative patients (-5.0 log vs. -4.5 l”
• EASL Clinical Practice Guidelines: management of chronic hepatitis B. (2009, background): “Entecavir and tenofovir are potent HBV inhibitors and they have a high barrier to resistance [38,58,59].”
• EASL clinical practice guidelines: Management of chronic hepatitis B virus infection. (2012, background): “Entecavir and tenofovir are potent HBV inhibitors with a high barrier to resistance [67,70,78,85,92,123] (Fig.”